根據 位華爾街分析師的預測,WuXi Biologics (Cayman) Inc. 的收入預期範圍從 $ 到 $
WuXi Biologics (Cayman) Inc. 的盈利品質評分是多少?
WuXi Biologics (Cayman) Inc. 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
WuXi Biologics (Cayman) Inc. 何時發布財報?
WuXi Biologics (Cayman) Inc. 的下一份財報預計在 2026-06-22 發布
WuXi Biologics (Cayman) Inc. 的預期收益是多少?
根據華爾街分析師的預測,WuXi Biologics (Cayman) Inc. 的預期收益為 $
WuXi Biologics (Cayman) Inc. 是否超出收益預期?
WuXi Biologics (Cayman) Inc. 最近的收益為 $, 預期。
關鍵數據
前收市價
$8.96
開盤價
$9.28
當日範圍
$8.9 - $9.28
52週區間
$4.14 - $11.21
交易量
2.1K
平均成交量
69.5K
股息收益率
--
每股盈餘 (TTM)
0.28
市值
$19.1B
什麼是 Wuxi Biologics (Cayman) Inc?
Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.